Patients with endometriosis exhibit a failure to increase expression of HOXA10 in the mid luteal phase, at the peak of the implantation window
Limitations and cautions with LL-37 include: It can be immune-activating: LL-37 may worsen symptoms in patients with high inflammation, MCAS, histamine intolerance, autoimmunity, or severe reactivity
Wegovy (semaglutide) targets GLP-1, while Zepbound (tirzepatide) targets GLP-1 and GIP
Another important white space is represented by the emergence of comorbidity-driven positioning of oral obesity drugs, which allows marketing such medicines as treatment not only for weight loss but also for obesity associated with type 2 diabetes, cardiovascular risks, metabolic syndrome, and MASH
A consultation can review the symptom you want to address, more established explanations and treatments, product sourcing, route options, potential interactions, and whether an elective IV is a reasonable choice
How Amari Health Supports Patients Exploring Peptide Therapy Amari Health focuses on individualized care designed to support metabolic health, weight loss, and overall wellness